Typical HUS is primarily a disease of childhood, most frequently occurring after an episode of bloody diarrhea caused by specific strains of E. coli , most notably O157:H7. The pathogenesis begins in the gut, where the bacterium releases Shiga toxin. This toxin enters the bloodstream and targets vascular endothelial cells, particularly those in the kidneys and brain. Shiga toxin directly damages these cells, triggering a local inflammatory response and exposing the underlying basement membrane. This leads to platelet adhesion, aggregation, and the formation of microthrombi in the small blood vessels of the renal glomeruli.
For aHUS, supportive care is insufficient. The therapeutic cornerstone is the blockade of terminal complement activation. The advent of eculizumab, a monoclonal antibody that inhibits the complement protein C5, has revolutionized the treatment of aHUS. This drug rapidly halts the thrombotic process, improves renal function, and prevents recurrence, including after transplantation. Without eculizumab or similar complement inhibitors, patients with aHUS face a lifetime of recurrent thrombotic crises and progressive organ failure. typical vs atypical hemolytic uremic syndrome
Clinically, typical HUS presents with a classic prodrome of several days of watery diarrhea followed by bloody diarrhea (dysentery). Approximately five to ten days after the onset of diarrhea, the triad of HUS manifests: pallor (anemia), petechiae and bruising (thrombocytopenia), and decreased urine output (acute kidney injury). The prognosis for typical HUS is surprisingly favorable. With aggressive supportive care—including meticulous fluid and electrolyte management, blood transfusions, and often dialysis—the majority of children recover renal function completely. The mortality rate is low (1-5%) in the acute phase, and long-term sequelae, such as chronic kidney disease or hypertension, occur in a minority of patients. Crucially, typical HUS is not a recurrent disease; once a patient recovers from the acute infection, the syndrome does not return. Typical HUS is primarily a disease of childhood,
Atypical HUS, in contrast, is a rare but devastating disease that can affect individuals of any age, from infancy to adulthood. Its name, "atypical," belies its clinical gravity. Unlike typical HUS, aHUS is not preceded by STEC infection. Instead, it is a primary disease of uncontrolled complement activation. In the majority of cases, aHUS is caused by inherited genetic mutations in complement regulatory proteins (e.g., factor H, factor I, MCP) or in activating proteins (e.g., factor B, C3). These mutations lead to a state of chronic, unchecked activation of the alternative complement pathway, resulting in persistent attack on the endothelium. This toxin enters the bloodstream and targets vascular
Hemolytic uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. While this definition is clear, the syndrome is not a single disease but rather a spectrum of conditions with vastly different etiologies, treatments, and prognoses. The critical distinction lies between typical HUS, also known as Shiga toxin-producing E. coli HUS (STEC-HUS), and atypical HUS (aHUS). Although they share a common final pathway of endothelial damage and microvascular thrombosis, their underlying mechanisms, clinical triggers, and long-term outcomes diverge so significantly that they are best understood as two distinct disorders: one an acute, often self-limited infection, the other a chronic, life-threatening genetic disease of complement dysregulation.
While aHUS can be triggered by an environmental insult (e.g., infection, pregnancy, surgery, certain medications), the fundamental problem is an intrinsic failure to regulate the complement cascade. This leads to systemic, recurrent, and progressive thrombotic microangiopathy, with a predilection for the kidneys but often affecting other organs such as the brain, heart, and gastrointestinal tract. The clinical presentation is variable and can lack the diarrheal prodrome typical of STEC-HUS. The prognosis for aHUS before the modern era was grim, with up to 50% of patients progressing to end-stage renal disease (ESRD) or death within the first year of diagnosis. Furthermore, aHUS is characterized by a high rate of recurrence, especially after kidney transplantation—indeed, the disease frequently destroys the transplanted organ unless the underlying complement dysregulation is addressed.
The fundamental differences between typical and atypical HUS dictate radically different management strategies. For typical HUS, treatment is supportive. Antibiotics are contraindicated as they may increase Shiga toxin release, and plasma exchange is generally ineffective. The key is to maintain hydration, manage electrolytes, and support renal function until the endothelium heals and the thrombotic process resolves spontaneously.
- By kievY
- By StefanN
- By lennarte